Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors

Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors

US Patent 8455629 · Granted Jun 4, 2013

Estimated economic value: $86,106,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Tumor necrosis factor-like ligand 1A specific antibodies and compositions and us2025
Anti-interleukin-23 P19 antibodies and methods of use thereof2025
Anti-CD27 antibodies and uses thereof2024
Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses there2023
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) 2023
Tumor necrosis factor-like ligand 1A specific antibodies and compositions and us2022
Anti-CLauDiN 18 antibodies and methods of use thereof2022
Anti-GITR antibodies for cancer diagnostics2022
Anti-interleukin-23 P19 antibodies and methods of use thereof2022
Antibodies against CD73 and uses thereof2022
Antibodies against MICA and/or MICB and uses thereof2022
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)2022